Home
>
National Drug Code (NDC)
>
Stribild
Stribild - 61958-1201-1 - (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Drug Information of Stribild
| Product NDC: | 61958-1201 |
| Proprietary Name: | Stribild |
| Non Proprietary Name: | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate |
| Active Ingredient(s): | 150; 150; 200; 300 mg/1; mg/1; mg/1; mg/1 & nbsp; elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Stribild
| Product NDC: | 61958-1201 |
| Labeler Name: | Gilead Sciences, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA203100 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20120827 |
Package Information of Stribild
| Package NDC: | 61958-1201-1 |
| Package Description: | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1201-1) |
NDC Information of Stribild
| NDC Code | 61958-1201-1 |
| Proprietary Name | Stribild |
| Package Description | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1201-1) |
| Product NDC | 61958-1201 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20120827 |
| Marketing Category Name | NDA |
| Labeler Name | Gilead Sciences, Inc. |
| Substance Name | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE |
| Strength Number | 150; 150; 200; 300 |
| Strength Unit | mg/1; mg/1; mg/1; mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
